Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : email@example.com
|Therapy Name||Idelalisib + Rituximab|
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|Idelalisib||Zydelig||CAL-101|GS-1101||PIK3CD inhibitor 27||Zydelig (idelalisib) inhibits PI3K-delta, preventing the activation of the PI3K signaling pathway and inhibiting tumor cell proliferation, motility, and survival (PMID: 24450857). Zydelig (idelalisib) is FDA approved for follicular B-cell non-Hodgkin lymphoma, relapsed small lymphocytic lymphoma, and in combination with Rituxan (rituximab) for relapsed chronic lymphocytic leukemia (FDA.gov).|
|Rituximab||Rituxan||IDEC-C2B8|MabThera||CD20 Antibody 21||Rituxan (rituximab) is a chimeric mononclonal antibody that binds to CD20 on B-cells, resulting in induction of complement-dependent and antibody-dependent cytotoxicity, and potentially leading to decreased B-cell tumor growth (PMID: 28983798). Rituxan (rituximab) is FDA approved for use as monotherapy or in combination with chemotherapy in CD20-positive B-cell non-Hodgkin lymphoma, in combination with fludarabine and cyclophosphamide in CD20-positive chronic lymphocytic leukemia, and in combination with chemotherapy in pediatric patients (6 month to 18 years of age) with treatment-naive, CD20-positive diffuse large B-cell lymphoma, Burkitt lymphoma, Burkitt-like lymphoma, or mature B-cell acute leukemia (B-AL) (FDA.gov).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|TP53 mutant||chronic lymphocytic leukemia||sensitive||Idelalisib + Rituximab||Guideline||Actionable||Zydelig (idelalisib) and Rituxan (rituximab) combination therapy is included in the guidelines as first-line therapy for patients with advanced chronic lymphocytic leukemia harboring TP53 mutations and for patients with relapsed or refractory disease (PMID: 33091559; ESMO.org).||detail... 33091559|
|TP53 loss||chronic lymphocytic leukemia/small lymphocytic lymphoma||sensitive||Idelalisib + Rituximab||Guideline||Actionable||Zydelig (idelalisib) combined with Rituxan (rituximab) is indicated in the guidelines as second line and subsequent therapy for chronic lymphocytic leukemia/small lymphocytic lymphoma patients with TP53 loss (NCCN.org).||detail...|
|TP53 mutant||chronic lymphocytic leukemia/small lymphocytic lymphoma||sensitive||Idelalisib + Rituximab||Guideline||Actionable||Zydelig (idelalisib) combined with Rituxan (rituximab) is indicated in the guidelines as second line and subsequent therapy for chronic lymphocytic leukemia/small lymphocytic lymphoma patients with a TP53 mutation (NCCN.org).||detail...|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status||Covered Countries||Other Countries|
|NCT02044822||Phase II||Idelalisib + Rituximab||Efficacy and Safety of Idelalisib in Combination With Rituximab in Patients With Previously Untreated Chronic Lymphocytic Leukemia With 17p Deletion||Terminated||USA | ITA | GBR | FRA | ESP | BEL | AUT | AUS||6|
|NCT04666038||Phase III||Idelalisib + Rituximab Pirtobrutinib Bendamustine + Rituximab||Study of LOXO-305 Versus Investigator's Choice (IdelaR or BR) in Patients With CLL or SLL||Recruiting||USA | ITA | GBR | FRA | ESP | DEU | CAN | BEL | AUT | AUS||14|